CTOs on the Move

CPC of America

www.cpcmeddevices.com

 
CPC of America is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Arcadia Resources

Arcadia Resources, Inc. is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Athletic Greens

Athletic Greens® supports gut health, immunity, energy, recovery, focus, aging, and more. Take control of your health routine and only take the supplements your body truly needs. Made in New Zealand. No artificial colors. Better absorption. Delivered t...

Mat-Su Health

The enjoyment of good health is fundamentally tied to the quality of life we enjoy here in the Mat-Su Borough. As such, Mat-Su Health Foundation`s focus in philanthropy is a natural extension of the historical work of Valley Hospital Association. The Mat-Su Health Foundation offers financial and strategic support to well-managed 501(c)(3) organizations that offer services and practical solutions to significant health-related problems impacting the citizens of the Mat-Su Borough. Some of our grant programs are open year-round, while others open for specific time periods. Please review our grant guidelines to see if your organization might be qualified to apply for funding. You may also review our searchable grants database to see the types of grants we have awarded in the past.

American College of Veterinary Surgeons

The American College of Veterinary Surgeons is the specialty board that defines the standards of surgical excellence for the field of veterinary medicine, promotes advancements in veterinary surgery, and provides the latest in veterinary surgical educa...

Scynexis

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.